Morgan Stanley Cuts Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target to $7.00

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) had its price objective dropped by research analysts at Morgan Stanley from $11.00 to $7.00 in a report released on Wednesday,Benzinga reports. The firm presently has an "underweight" rating on the stock. Morgan Stanley's target price would indicate a potential upside of 35.66% from the stock's current price.

A number of other brokerages have also commented on YMAB. Wedbush reaffirmed an "outperform" rating and set a $23.00 price objective on shares of Y-mAbs Therapeutics in a research report on Monday, March 3rd. HC Wainwright reissued a "buy" rating and issued a $22.00 price target on shares of Y-mAbs Therapeutics in a research report on Monday, January 13th. Oppenheimer began coverage on shares of Y-mAbs Therapeutics in a research report on Monday, November 18th. They issued an "outperform" rating and a $23.00 price target for the company. Finally, Brookline Capital Management began coverage on shares of Y-mAbs Therapeutics in a research report on Thursday, December 5th. They issued a "buy" rating and a $17.00 price target for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $19.30.

Remove Ads

Y-mAbs Therapeutics Trading Down 1.7 %

NASDAQ:YMAB traded down $0.09 during trading hours on Wednesday, hitting $5.16. 323,344 shares of the stock traded hands, compared to its average volume of 470,860. The firm has a 50 day moving average price of $6.28 and a 200 day moving average price of $10.47. Y-mAbs Therapeutics has a fifty-two week low of $4.25 and a fifty-two week high of $18.10. The firm has a market cap of $231.11 million, a price-to-earnings ratio of -9.56 and a beta of 0.65.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The company had revenue of $26.50 million for the quarter, compared to analysts' expectations of $26.70 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. During the same quarter in the prior year, the firm earned ($0.02) earnings per share. Research analysts predict that Y-mAbs Therapeutics will post -0.65 EPS for the current year.

Institutional Trading of Y-mAbs Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Infinitum Asset Management LLC bought a new stake in Y-mAbs Therapeutics during the fourth quarter worth about $1,218,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Y-mAbs Therapeutics by 17.4% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 52,356 shares of the company's stock worth $410,000 after buying an additional 7,765 shares during the last quarter. Two Sigma Investments LP grew its stake in shares of Y-mAbs Therapeutics by 31.6% during the fourth quarter. Two Sigma Investments LP now owns 88,337 shares of the company's stock valued at $692,000 after purchasing an additional 21,196 shares during the last quarter. Rafferty Asset Management LLC grew its stake in shares of Y-mAbs Therapeutics by 17.6% during the fourth quarter. Rafferty Asset Management LLC now owns 41,255 shares of the company's stock valued at $323,000 after purchasing an additional 6,178 shares during the last quarter. Finally, ProShare Advisors LLC bought a new stake in shares of Y-mAbs Therapeutics during the fourth quarter valued at approximately $99,000. 70.85% of the stock is owned by institutional investors.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.